Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Semaglutide (SEMA) is a metabolic peptide, at the fda approved stage in the published literature. GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy.
GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy.
| Research Status | FDA approved |
|---|---|
| Half-Life | ~7 days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 0.25-2.4 mg weekly |
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity.
GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Brand names include Ozempic and Wegovy.
GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity.
Semaglutide is at the following stage in the published literature: FDA approved. All information is for research and educational purposes only.
Reported half-life: ~7 days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.